- Correction
- Open access
- Published:
Correction: Differential response to donepezil in MRI subtypes of mild cognitive impairment
Alzheimer's Research & Therapy volume 15, Article number: 177 (2023)
Correction: Alz Res Ther 15, 117 (2023)
https://doi.org/10.1186/s13195-023-01253-2
Following publication of the original article [1], the authors identified an error to the titles and labels of axes in Figs. 3 and 4, as well as the captions of treatment groups on Fig. 4. This error does not affect the accuracy and clarity of the research presented, neither does affect the interpretation of the results. The corrected figures are given below.
Error:
-
In Fig. 3A (Scatterplot of the hippocampus-to-cortex ratio by BV/CSF index), labels indicating the MRI subtypes are in the reverse order.
-
In the X axis, which corresponds to the “TYPICALITY-Hippocampus-to-cortex ratio”, labels should go from “Limbic-predominant” (on the left) to “Hippocampal-sparing” (on the right).
-
In the Y axis, which corresponds to the “SEVERITY-BV:CSF index”, labels should go from “Minimal atrophy” (at the top) to “Typical AD” (at the bottom).
-
-
In Fig. 4 (interaction plots between severity/typicality subtyping dimension and treatment in the MRI efficacy measures), captions of the lines indicating the treatment groups are in reversed order. Red lines correspond to the placebo group (not to the donepezil group), and blue lines correspond to the donepezil group (not to the placebo group).
-
In Fig. 4C (interaction plot between typicality subtyping dimension and APC of lateral ventricle volume), axes titles are incorrect.
-
X axis title should be “TYPICALITY-Hippocampus-to-cortex ratio”, instead of “SEVERITY-BV:CSF index”.
-
Y axis title should be “APC Lateral Ventricle vol”, instead of "APC AD Signature cortical thickness”. Labels on the Y axis are also incorrect. They should be changed to “Increased atrophy rate” (at the top) and “Reduced atrophy rate” (at the bottom).
-
The original article [1] has been updated.
Reference
Diaz-Galvan P, Lorenzon G, Mohanty R, et al. Differential response to donepezil in MRI subtypes of mild cognitive impairment. Alz Res Therapy. 2023;15:117. https://doi.org/10.1186/s13195-023-01253-2.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Diaz‑Galvan, P., Lorenzon, G., Mohanty, R. et al. Correction: Differential response to donepezil in MRI subtypes of mild cognitive impairment. Alz Res Therapy 15, 177 (2023). https://doi.org/10.1186/s13195-023-01320-8
Published:
DOI: https://doi.org/10.1186/s13195-023-01320-8